Rationale: Antipsychotic polypharmacy (APP) is commonly used in schizophrenia despite a lack of robust evidence for efficacy, as well as evidence of increased rates of adverse drug reactions and mortality. Objectives: We sought to examine APP and the use of other adjunctive medications in patients with treatment-resistant schizophrenic disorders (ICD-10 diagnoses F20-F29) immediately prior to clozapine initiation, and to investigate clinical and sociodemographic factors associated with APP use in this setting. Methods: Analysis of case notes from 310 patients receiving their first course of clozapine at the South London and Maudsley NHS Trust (SLaM) was undertaken using the Clinical Record Interactive Search (CRIS) case register. Medication taken immediately prior to clozapine initiation was recorded, and global clinical severity was assessed at time points throughout the year prior to medication assessment using the Clinical Global Impression -Severity scale (CGI-S). Logistic regression was used to investigate factors associated with APP. Results: The point prevalence of APP prior to clozapine initiation was 13.6% (n=42), with 32.6% of subjects prescribed adjuvant psychotropic medications. APP was associated with increasing number of adjuvant medications (odds ratio (OR) 1.97, 95% confidence interval (CI) 1.27-3.06), concurrent depot antipsychotic prescription (OR 2.64, CI 1.24-5.62), concurrent antidepressant prescription (OR 4.40, CI 1.82-10.63) and a CGI-S over the previous year within the two middle quartiles (Quartile 2 vs 1 OR 6.19, CI 1.81-21.10; Quartile 3 vs 1 OR 4.45, CI 1.29-15.37; Quartile 4 vs 1 OR 1.88, CI 0.45-7.13). Conclusions: APP and augmentation of antipsychotics with antidepressants, mood stabilizers and benzodiazepines are being employed in treatmentresistant schizophrenia prior to clozapine. The conservative APP rate observed may have been influenced by an initiative within SLaM that reduced APP rates during the study window. Efforts to reduce the use of poorly evidenced prescribing should focus on adjuvant medications as well as APP.
Introduction
Antipsychotic polypharmacy (APP), the concurrent use of two or more antipsychotics, remains common in the UK, with 38% of all psychiatric inpatients and 16% of those with schizophrenia living in the community prescribed multiple antipsychotics (Mace and Taylor, 2015; Patel et al. 2014) . Analysis of the national Danish health registers demonstrated wide geographical variation in APP utilization, and whilst its use decreased between 2006 and 2012, it remains more prevalent than in 1996 (Sneider et al., 2015) .
A number of factors contribute to the use of APP. From the limited number of studies that examine APP in schizophrenia, individuals with treatment resistance, the failure to respond to adequate courses of two different antipsychotics, show much higher rates of APP (Schmidt-Kraepelin et al., 2013) . Ineffectual Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders control of symptoms may lead to clinicians prescribing multiple antipsychotics, and improvement during cross-titration between antipsychotics may lead to long-term prescribing of both drugs. Additional antipsychotics, sometimes used initially as 'as required' medication, may be introduced as regular medication for patients with aggression or short-term distress and agitation, leading to long-term use. Grech and Taylor (2014) found 39% of patients were prescribed long-term APP (>6 months) after 0 or 1 monotherapy trials, and that less than half of those prescribed APP had been trialled on clozapine.
Despite the widespread use of APP, evidence regarding efficacy over monotherapy in treatment resistance is both limited and equivocal, particularly for non-clozapine combinations of APP. Clozapine monotherapy has been demonstrated in individual studies and meta-analyses to reduce symptoms in treatmentresistant patients, and is more efficacious than other second generation antipsychotics (Lewis et al, 2006; McEvoy et al., 2006; Wahlbeck et al., 1999) . Small open-label trials have demonstrated varying levels of symptom improvement when nonclozapine combinations of APP were utilized (Lerner et al., 2000 (Lerner et al., , 2005 Potkin et al., 2002; Zink et al., 2004,) . However, a metaanalysis of 19 APP trials by Correll et al. (2009) suggested that publication bias may have been present, with larger studies showing smaller effects, and the greatest effect evident when clozapine was included in the APP regimen. In particular, a large scale randomized controlled trial with 323 subjects found no improvement in symptoms when adjunctive aripiprazole or placebo were used in combination with either risperidone or quetiapine (Kane et al., 2009) . Meanwhile, some studies investigating augmentation of clozapine have demonstrated efficacy in positive symptom reduction (Josiassen et al., 2005; Muscatello et al., 2011) , whilst others suggest the adjunctive use of aripiprazole can reduce metabolic side effects (Henderson et al., 2006) . In addition to questionable efficacy, APP is associated with an increase in adverse drug reactions and hospitalization (Centorrino et al., 2004) , mortality (Waddington et al., 1998) , and higher antipsychotic doses (Roh et al., 2014) . At present there is insufficient evidence to support the use of any particular combination of non-clozapine antipsychotics.
In view of the lack of evidence for APP, national efforts have been made to reduce APP in the UK since 2009, when the National Institute for Health and Care Excellence (NICE) issued guidance recommending the avoidance of APP, except for the augmentation of clozapine in treatment-resistant patients who are unresponsive to clozapine alone. Despite this, existing research suggests that this guidance has not been fully incorporated into clinical practice (Grech and Taylor, 2012) . A systematic review concluded that careful switching from APP to monotherapy is feasible for most patients (Tani et al, 2013) , but a large-scale quality improvement programme in the UK demonstrated little change in APP rates, with a baseline rate of 43% amongst adult inpatients, and a re-audit rate of 39% (Paton et al., 2008) . In addition, Howes et al. (2012) reported the prescription of clozapine was preceded by a mean theoretical delay of 47.7 months from when patients were first eligible for clozapine therapy, with 36.2% of patients receiving APP during this time.
Evidence regarding the efficacy of adjunctive antidepressants or mood stabilizers is also inconclusive (Leucht et al., 2007; Rummel et al., 2006; Schwarz et al., 2008; Sepehry et al., 2007) , whilst benzodiazepines have been found to have no effect beyond short term sedation. (Volz et al., 2007) . In addition to concerns regarding efficacy, there are not enough data regarding adverse effects and long-term safety to recommend any of these adjunctive strategies for routine clinical use.
It remains unclear how current evidence and guidance for APP in adults with treatment-resistant schizophrenia are applied clinically. There are very few UK-based naturalistic studies of APP in schizophrenia, and, as yet, no detailed examination of the sociodemographic and clinical predictors of non-clozapine APP in treatment-resistant patients. In addition, to date no studies have investigated the use of both APP and augmentation with other classes of psychotropic drugs concurrently.
So that psychopharmacological prescribing practices are better understood in treatment-resistant schizophrenia, we sought to investigate the use of APP and the use of antipsychotic augmentation with mood stabilizers, antidepressants and benzodiazepines. Using a retrospective cohort design, in a sample of patients with treatment-resistant schizophrenia, we examined the sociodemographic and clinical factors associated with APP prior to first-ever clozapine use.
Methods

Study setting
The cohort was identified within the South London and Maudsley (SLaM) Biomedical Research Council Case Register. SLaM is a National Health Service (NHS) mental health trust that provides secondary mental health services to a population of 1.2 million in the boroughs of Lambeth, Southwark, Lewisham and Croydon in south-east London, a population where age, gender, education and levels of social deprivation are comparable to the wider population of London (Stewart et al., 2009 ). The Clinical Record Interactive Search (CRIS) system, described in detail elsewhere (Stewart et al., 2009) , allows researchers to access de-identified copies of patient's electronic health records which have been in use across the trust since 2006. A general architecture for text engineering (GATE) application within CRIS was used to identify patients who fulfilled the inclusion criteria for this study (Figure 1 ). Eligibility was then manually confirmed by accessing full-text anonymised case notes in the user interface of CRIS.
Inclusion criteria
310 patients were eligible for inclusion ( Figure 1 ). Individuals aged 18-65 years with an ICD-10 F20-F29 diagnosis and who were prescribed clozapine for the first time between 1 January 2007 and 31 December 2011 were included. Subjects were receiving care as either inpatients or outpatients under secondary mental health services provided by SLaM. National patients referred from out-of-area for clozapine initiation were excluded as they are not representative of the study population and frequently lacked data on prescribing prior to clozapine initiation.
Outcome measures
The main outcome measure in this study was use of APP immediately prior to clozapine initiation in those with an ICD-10 F20-F29 diagnosis. In addition, the use of adjunctive antidepressants, mood stabilizers and benzodiazepines was assessed. A retrospective analysis of full-text anonymised case notes (inpatient and community notes, correspondence between clinicians and external agencies) was undertaken within the CRIS system, and medications prescribed were manually recorded, taken from the clinical entries closest in time to clozapine initiation that contained sufficient information. Antipsychotics, mood stabilizers, antidepressants and benzodiazepines prescribed for regular use were recorded, along with route of administration. APP was defined as the concurrent use of more than one regular antipsychotic drug. In subjects where no antipsychotic prescription prior to clozapine initiation was evident in the immediately preceding case notes, evaluation of the previous six months case notes was undertaken to confirm subjects were not receiving antipsychotics. Thirteen patients were prescribed both oral and depot risperidone, and these patients were not included in the APP group, since this practice is recommended during risperidone depot initiation.
Explanatory variables
The main factors of interest in this study were clinical severity, concurrent use of adjuvant psychoactive medications and sociodemographic factors. In order to evaluate the relationship between APP use and clinical severity, manual analysis of case notes in the CRIS system was undertaken, using the Clinical Global Impression Severity scale (CGI-S) to assess symptomatology and functioning immediately prior to clozapine initiation, as well as at 1, 3, 6, 9 and 12 months prior to clozapine therapy. Average CGI-S over the year prior to medication data collection was calculated for each patient. Case notes dated up to the midpoint between time points were used when assessing CGI-S, to ensure that an accurate reflection of psychopathology over the year was obtained. For example, entries from 4.5 months to 7.5 months were eligible for use in assessing the 6-month time point. A variety of source material was used for each assessment, to allow both symptoms and social functioning to be assessed (ward round notes, nursing notes, community notes, correspondence), in addition to minimizing potential bias from individual sources. Inter-rater reliability for CGI-S rating was calculated using twoway mixed effect model intra-class correlation coefficients. The absolute individual intra-class correlation coefficient for all four raters (JVT, JMC, SEL, JD) was 0.71, indicating substantial agreement. Data regarding the use of adjuvant psychoactive medications was collected at a single time point for each patient prior to clozapine initiation, as described above. Number of adjuvant medications was defined as the total number of antidepressants, mood stabilizers and regular benzodiazepines prescribed to each patient in addition to antipsychotics.
Age, gender, ethnicity, ICD-10 diagnosis and whether patients were detained under the Mental Health Act (MHA) at clozapine initiation were extracted from structured fields within CRIS. Age was defined as age at start of clozapine treatment. Ethnicity was categorized into three groups -White British or other white background, African Caribbean or other black background and Other. Social deprivation was estimated using the 'Index of Multiple Deprivation', with area-level deprivation scores available in CRIS based on postal codes and data from the 2007 UK Census, and was categorized into high, medium and low levels of deprivation. The Index of Multiple Deprivation is calculated based upon employment, health, education, housing, crime and environment. APP point prevalence in SLaM inpatients was 
Statistical analysis
Crude analysis of factors associated with APP prior to clozapine initiation was carried out using Pearson's χ 2 for categorical variables and logistic regression for continuous variables. Logistic regression was used for multivariable analysis. The logistic regression model was adjusted for all variables that appear within Table 1 , with the exception of 'increasing number of adjunctive medications' as this was highly correlated with mood stabilizer, antidepressant and benzodiazepine prescription. Likelihood ratio tests indicated that it was appropriate to include average CGI-S over the year prior to medication review as an ordered categorical variable (quartiles) and age as a continuous variable. Stata 13 was used for all statistical analysis.
Ethical approval
Ethical approval for the use of CRIS as a research dataset was given by Oxfordshire Research Ethics Committee C (08/ H0606/71). Permission for this study was granted by the CRIS oversight committee.
Results
64.5% of the cohort was male, and 91% of subjects had an ICD-10 diagnosis of schizophrenia (F20). Black Africans and Caribbeans comprised 47.7% of the cohort whilst White subjects comprised 40.0%.
Antipsychotic polypharmacy
13.6% of patients (n=42) were prescribed APP immediately prior to clozapine initiation (Table 1) , of whom 22 were prescribed two oral antipsychotics and 17 were prescribed concurrent oral and depot medication. Amisulpride combined with quetiapine was the most commonly prescribed individual regimen of APP (n=6), with 28 different combinations of antipsychotics used across the 42 instances of APP.
Factors associated with antipsychotic polypharmacy
Increasing number of adjuvant medications (antidepressants, mood, stabilizers, benzodiazepines) was associated with APP (Table 1 , odds ratio (OR) 1.97, 95% confidence interval (CI) 1.27-3.06). Multivariable analysis indicated that individuals with an average CGI-S within the two middle quartiles (4.33-5.17) over the year prior to clozapine initiation were more likely to be prescribed APP prior to clozapine initiation ( 1.29-15.37, Q4 vs Q1 OR 1.88, CI 0.45-7.13). In addition, the prescription of antidepressants (OR 4.40, CI 1.82-10.63), and depot preparations of antipsychotics (OR 2.64, CI 1.24-5.62) were associated with increased use of APP, whilst the prescription of mood stabilizers and benzodiazepines was not. Age, gender, ethnicity, diagnosis, detention under the MHA at clozapine initiation and socioeconomic status were not significantly associated with APP. APP decreased year-on-year throughout the study window, from 18.2% in 2007 to 11.4% in 2011. These results are in line with the reduction in APP across the trust due to the quality improvement programme implemented within SLaM between 2006 and 2012, which aimed to reduce APP and high dose prescribing ( Figure 2 ).
Adjuvant medication
32.6% of patients (n=101) were prescribed one or more adjuvant medications (mood stabilizers, antidepressants, benzodiazepines) in addition to antipsychotics (Table 2) . Sodium valproate (n=27) and lithium (n=7) were the most frequently prescribed adjunctive mood stabilizers (11.9% of cohort, n=37), whilst citalopram (n=17) and mirtazapine (n=8) were the most commonly prescribed antidepressants (15.2% of cohort, n=47). Regular benzodiazepines were prescribed to 11.6% (n=36), with clonazepam (n=23) used more frequently than diazepam (n=13).
Monotherapy 60.0% of patients were prescribed oral monotherapy, with olanzapine (n=68, 36.6% of oral monotherapy) and risperidone (n=44, 23.4% of oral monotherapy) the most commonly prescribed drugs. Depot monotherapy was prescribed to 18.7% of patients, with zuclopenthixol decanoate (n=19, 32.7% of all depot monotherapy) and risperidone depot (n=13, 22.4% of all depot monotherapy) most commonly utilized. In addition, 4.2% of patients (n=13) were prescribed both depot and oral risperidone. Of 11 patients who were prescribed no antipsychotics prior to clozapine initiation, seven were taking no psychoactive medication at all whilst the remainder were prescribed either mood stabilizers or antidepressants.
Discussion
Summary of main findings
The point prevalence of APP prior to clozapine initiation was 13.5% within our cohort of treatment-resistant adults, with 28 different combinations of APP prescribed. The use of antidepressants, mood stabilizers and regular benzodiazepines was common, with 32.6% of patients prescribed at least one of these medications, and APP was associated with increasing number of adjuvant medications prescribed. Specifically, the prescription of antidepressants and depot antipsychotics was strongly associated with APP, whilst no association was evident between APP and the prescription of benzodiazepines or mood stabilizers. Subjects whose average CGI-S was within the two middle quartiles were much more likely to be prescribed APP than subjects whose CGI-S was within either the least or more severe quartile. No association was found between APP and any sociodemographic factors investigated.
Comparison to other studies
Our findings add to previous evidence that APP is being used inappropriately prior to clozapine, delaying use of this goldstandard medication. Whilst we report a point prevalence of APP prior to clozapine initiation, prescription surveys undertaken in SLaM during 2003 and 2012 note lifetime prevalence rates of APP prior to clozapine initiation of 65% and 32.6%, respectively (Howes et al., 2012; Taylor et al., 2003) , with Howes et al.
reporting that this contributed to a mean theoretical delay to clozapine initiation of 47.7 months in their cohort. Higher APP point prevalence has been demonstrated amongst inpatients within SLaM, with rates falling during this study's period of observation from 37% in 2007 to 16% in 2012 (Mace and Taylor, 2015) . In contrast to higher levels of inpatient APP, a large study of both community and inpatient subjects within SLaM with serious mental illness (SMI) diagnoses (schizophrenia, bipolar affective disorder, schizo-affective disorder) estimated that 4.7% were prescribed long-term APP for at least six months (Kadra et al., 2015) .
No other studies to date have reported the prevalence of antidepressant, mood stabilizer and benzodiazepine prescribing in addition to APP. Studies in the wider population with schizophrenia identified greater use of adjuvant psychotropic medications; antidepressants were prescribed to 38% of patients, anxiolytics to 22% and mood stabilizers to 19% in a large study carried out in the USA (Chakos et al, 2006) . An Austrian study further demonstrated high rates of adjuvant psychotropic medication use, but noted large variation in use between different clinics (Ritmannsberger et al., 1999) .
Previous research has recognized severity of schizophrenia as a predictor of APP (Connolly and Taylor, 2014) . Our results partially support this, suggesting APP is less common in those with milder symptoms, but also less common in those with the most severe symptoms. This finding could indicate a possible lowering of average CGI-S due to the use of APP. Few studies have investigated the role of sociodemographic factors in APP. Male gender has been linked with APP previously (Suokas et al., 2013) , but we found no association between gender and APP prior to clozapine treatment. However, treatment resistance is more common amongst men (Seeman, 1982) , who comprised almost two thirds of the cohort, potentially confounding an association. Socioeconomic status was found not to impact upon APP prescribing in our study, in keeping with results from a large Scottish study (Martin et al., 2014) . We identified six patients who were prescribed a combination of quetiapine and amisulpride, representing 14.3% of APP. The evidence underlying this strategy is limited -one case series of six patients partially responsive to quetiapine monotherapy who exhibited a reduction in psychotic symptoms with the addition of amisulpride (Englisch et al., 2010) . However, subjects within this series gained an average of 6 kg, and prolactin levels increased four-fold with the introduction of amisulpride, highlighting the potential for increased adverse drug reactions with APP.
Strengths
As a provider of secondary mental health services within the UK NHS, SLaM has close to a 100% monopoly in providing care for those with schizophrenia with a catchment area containing 1.2 million people, leading to minimal selection bias. The procedure to detect medication use used data from pharmacy dispensing and structured medication fields, as well as Natural Language processing (using the GATE application), to extract medications data from free-text, including clinical notes and correspondence between clinicians and other agencies. The use of multiple sources of information allows for both high recall and precision and, additionally, the medication application has been validated against manual search methods. Manual screening for eligibility was subsequently undertaken to ensure all subjects met the inclusion criteria for the study. The GATE medication application was utilized for identifying subjects due to its high level of recall, whilst analysis of case notes was undertaken manually to allow for both high recall and precision. Studies investigating APP often fail to identify subjects who are undergoing cross-titration between antipsychotics, for whom APP is required in the short term to ensure adequate plasma levels of medication. As subjects in our study were being 'worked up' for clozapine initiation, it is unlikely that many of them were undergoing cross-titration between other antipsychotics, minimizing the effect of crosstitration on the reported prevalence.
Limitations
Our study window coincided with the implementation of a quality improvement programme within the trust that aimed to reduce APP and high-dose prescribing, and the effectiveness of this programme means that results may not be generalizable to other trusts or regions (Mace and Taylor, 2015) . Prescribed medications were assessed only at a single time point due to the labour intensive nature of assessing full-text case notes. Therefore, we report a point prevalence of APP prior to clozapine initiation, and are unable to identify how many patients were prescribed APP on a long term basis, or those subjects who had been prescribed APP historically, but were receiving monotherapy immediately prior to clozapine initiation.
APP was associated only with those subjects whose average CGI-S was within the two middle quartiles, and not with those subjects whose average CGI-S fell into the uppermost quartile, representing those with the most severe psychopathology. Whilst this finding could indicate a possible lowering of average CGI-S due to the use of APP, it must be interpreted with caution, due to the uncertain temporal relationship between APP prescription and symptom severity, as it is not known for how long subjects were prescribed APP. The inclusion of patients with a diagnosis of schizo-affective disorder may explain some cases of mood stabilizer and antidepressant use prior to clozapine initiation, although the prevalences of antidepressant and mood stabilizer prescription were around two and threefold greater than the rates of schizo-affective diagnoses. Finally, case notes were often unclear as to whether benzodiazepines were prescribed on a regular or as required basis, and, as such, their use may be under-reported.
Implications
Our findings have important implications for prescribers and future guidelines. We found that whilst the prevalence of APP in treatment-resistant adults prior to clozapine therapy was relatively low, the use of other poorly-evidenced adjunctive medications was both common and also more frequently observed in those prescribed APP. This observation suggests that some prescribers are seeking to overcome treatment resistance through the addition of further drugs to already poorly-evidenced regimens. Of particular note is the marked association between antidepressant use and APP. Further research is required to better understand the extent to which this relationship is driven by an increased incidence of comorbid depression in treatment-resistant individuals, misdiagnosis of affective disorders with psychotic features or a failure of antipsychotics to adequately treat the negative symptoms of schizophrenia.
The large number of different antipsychotic combinations prescribed suggests that what little evidence is available rarely factors in to clinical decision-making when APP is used. There are many factors that influence clinicians' decisions to implement APP or other augmentation strategies in preference to clozapine. Both clinicians' own preferences and views held by patients regarding clozapine are influenced by concerns surrounding adverse effects, adherence and required monitoring protocols, as well as a persisting lack of knowledge regarding clozapine's superior efficacy (Patel, 2012) . APP use, whilst modest in our cohort, contributes to delay in treatment with clozapine (Howes et al., 2012) . Longer duration of inadequately treated psychosis is associated with poorer outcomes, both in terms of symptoms and overall functioning (Perkins et al., 2005) . Whilst clinicians and patients may have negative perceptions of clozapine, it remains a betterevidenced treatment than APP in terms of efficacy and safety.
